Predictive value of early and late residual F-18-fluorodeoxyglucose and F-18-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib

C. Kobe; M. Scheffler; A. Holstein; T. Zander; L. Nogova; A.A. Lammertsma; R. Boellaard; B. Neumaier; R.T. Ullrich; M. Dietlein; J. Wolf; D. Kahraman

doi:10.1007/s00259-012-2118-8

Predictive value of early and late residual F-18-fluorodeoxyglucose and F-18-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib

C. Kobe, M. Scheffler, A. Holstein, T. Zander, L. Nogova, A.A. Lammertsma, R. Boellaard, B. Neumaier, R.T. Ullrich, M. Dietlein, J. Wolf, D. Kahraman

Radiology and nuclear medicine

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	1117-1127
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	39
Issue number	7
DOIs	https://doi.org/10.1007/s00259-012-2118-8
Publication status	Published - 2012

Access to Document

10.1007/s00259-012-2118-8

Cite this

Kobe, C., Scheffler, M., Holstein, A., Zander, T., Nogova, L., Lammertsma, A. A., Boellaard, R., Neumaier, B., Ullrich, R. T., Dietlein, M., Wolf, J., & Kahraman, D. (2012). Predictive value of early and late residual F-18-fluorodeoxyglucose and F-18-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. European Journal of Nuclear Medicine and Molecular Imaging, 39(7), 1117-1127. https://doi.org/10.1007/s00259-012-2118-8

@article{358592c4a5bc438aabc22f7a63cb7a7b,

title = "Predictive value of early and late residual F-18-fluorodeoxyglucose and F-18-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib",

author = "C. Kobe and M. Scheffler and A. Holstein and T. Zander and L. Nogova and A.A. Lammertsma and R. Boellaard and B. Neumaier and R.T. Ullrich and M. Dietlein and J. Wolf and D. Kahraman",

year = "2012",

doi = "10.1007/s00259-012-2118-8",

language = "Undefined/Unknown",

volume = "39",

pages = "1117--1127",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "Springer Verlag",

number = "7",

}

Kobe, C, Scheffler, M, Holstein, A, Zander, T, Nogova, L, Lammertsma, AA , Boellaard, R, Neumaier, B, Ullrich, RT, Dietlein, M, Wolf, J & Kahraman, D 2012, 'Predictive value of early and late residual F-18-fluorodeoxyglucose and F-18-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib', European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 7, pp. 1117-1127. https://doi.org/10.1007/s00259-012-2118-8

Predictive value of early and late residual F-18-fluorodeoxyglucose and F-18-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. / Kobe, C.; Scheffler, M.; Holstein, A. et al.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 39, No. 7, 2012, p. 1117-1127.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Predictive value of early and late residual F-18-fluorodeoxyglucose and F-18-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib

AU - Kobe, C.

AU - Scheffler, M.

AU - Holstein, A.

AU - Zander, T.

AU - Nogova, L.

AU - Lammertsma, A.A.

AU - Boellaard, R.

AU - Neumaier, B.

AU - Ullrich, R.T.

AU - Dietlein, M.

AU - Wolf, J.

AU - Kahraman, D.

PY - 2012

Y1 - 2012

U2 - 10.1007/s00259-012-2118-8

DO - 10.1007/s00259-012-2118-8

M3 - Article

C2 - 22526960

VL - 39

SP - 1117

EP - 1127

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 7

ER -

Kobe C, Scheffler M, Holstein A, Zander T, Nogova L, Lammertsma AA et al. Predictive value of early and late residual F-18-fluorodeoxyglucose and F-18-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. European Journal of Nuclear Medicine and Molecular Imaging. 2012;39(7):1117-1127. doi: 10.1007/s00259-012-2118-8